v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash $ 21,237 $ 139,360
Accounts receivable, net 67,694 253,459
Grant receivable 102,613 52,026
Inventory 43,551 143,425
Prepaid expenses 388,282 226,198
Total current assets 623,377 814,468
Property and equipment, net 0 4,062
Right to use assets 137,869 159,128
Other assets:    
Intangible assets, net 541,119 564,460
Goodwill 563,158 563,158
Deposits, long term 41,936 41,936
Total other assets 1,146,213 1,169,554
Total assets 1,907,459 2,147,212
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $1,448,722 and $1,271,685, respectively 6,763,370 6,362,728
Deferred revenue, grant 1,040 0
Lease liability, short term 45,146 43,382
Notes payable, net of debt discount of $0 1,271,884 1,222,730
Notes payable, related parties, net of debt discount of $0 773,263 677,359
Total current liabilities 8,854,703 8,306,199
Long term liabilities:    
Economic Injury Disaster loan, long term 68,770 69,537
Upfront purchase price liability 0 42,503
Royalty liability 348,155 359,378
Royalty obligation, net of discount of $3,707,374 and $3,941,262, related parties 5,014,726 4,780,838
Lease liability, long term 92,723 115,745
Total liabilities 14,379,077 13,674,200
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 29,666,506 and 24,489,311 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 29,666 24,489
Common stock subscribed 100,000 100,000
Additional paid in capital 76,183,780 75,279,624
Accumulated deficit (88,559,898) (86,649,288)
Total deficit attributable to BioCorRx Inc. (12,224,836) (11,223,559)
Non-controlling interest (246,782) (303,429)
Total deficit (12,471,618) (11,526,988)
Total liabilities and deficit 1,907,459 2,147,212
Series A Convertible Preferred Stock [Member]    
Deficit:    
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025 16,000 16,000
Series B Convertible Preferred Stock [Member]    
Deficit:    
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025 $ 5,616 $ 5,616